Cargando…

Efficacy and safety of IL inhibitors, TNF-α inhibitors, and JAK inhibitors in patients with ankylosing spondylitis: a systematic review and Bayesian network meta-analysis

BACKGROUND: Biologics and Janus kinase (JAK) inhibitors are commonly used to improve ankylosing spondylitis (AS) symptoms if conventional treatments are ineffective or unsuitable. This systematic review aimed to compare the therapeutic effects and safety of JAK inhibitors, tumor necrosis factor-alph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Cong, Shu, Jianlong, Shao, Wenhui, Zhou, Zhengxin, Guo, Huayang, Wang, Jingang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009571/ https://www.ncbi.nlm.nih.gov/pubmed/36923085 http://dx.doi.org/10.21037/atm-23-195

Ejemplares similares

Serum Metabolomics Signatures Associated With Ankylosing Spondylitis and TNF Inhibitor Therapy
por: Ou, Jiayong, et al.
Publicado: (2021)

Treatment of ankylosing spondylitis with TNFα inhibitors does not affect serum levels of tryptophan metabolites
por: Witoszyńska-Sobkowiak, Joanna, et al.
Publicado: (2023)

Reparative radiological changes of hip joint after TNF inhibitors in ankylosing spondylitis
por: Maatallah, Kaouther, et al.
Publicado: (2018)

Machine learning to predict early TNF inhibitor users in patients with ankylosing spondylitis
por: Lee, Seulkee, et al.
Publicado: (2020)

Factors affecting drug survival of an alternative TNF inhibitor and secukinumab in patients with ankylosing spondylitis switching from the first TNF inhibitor
por: Kwon, Oh Chan, et al.
Publicado: (2021)

Ankylosing spondylitis disease activity score is related to NSAID use, especially in patients treated with TNF-α inhibitors
por: Carbo, Marlies J. G., et al.
Publicado: (2018)

The relationship between blood eosinophil count and disease activity in ankylosing spondylitis patients treated with TNF-α inhibitors
por: Sargin, Gokhan, et al.
Publicado: (2018)

Anti-TNF-α Therapy for Ankylosing Spondylitis
por: Son, Jung-Hwan, et al.
Publicado: (2010)

Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis
por: Liu, Wei, et al.
Publicado: (2016)

Interleukin-17 Inhibitors for the Treatment of Ankylosing Spondylitis
por: Huang, Jin-Xian, et al.
Publicado: (2020)

Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors: a cross-sectional study
por: Wroński, Jakub, et al.
Publicado: (2019)

Prevalence and complication of COVID‐19 in patients with ankylosing spondylitis (AS) and its relationship with TNF‐a inhibitors
por: Movassaghi, Shafieh, et al.
Publicado: (2023)

Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis
por: Yin, Yufeng, et al.
Publicado: (2020)

Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?
por: Gialouri, Chrysoula G., et al.
Publicado: (2022)

Efficacy of TNF inhibitors in advanced ankylosing spondylitis with total spinal fusion: case report and review of literature
por: Shim, Man R
Publicado: (2019)

PBMC CDC42 reveals the disease activity and treatment efficacy of TNF inhibitor in patients with ankylosing spondylitis
por: Zhang, Qian, et al.
Publicado: (2022)

Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea
por: Jeong, Hyemin, et al.
Publicado: (2018)

Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
por: Lauper, Kim, et al.
Publicado: (2022)

IL-33 Gene Polymorphisms as Potential Biomarkers of Disease Susceptibility and Response to TNF Inhibitors in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Patients
por: Iwaszko, Milena, et al.
Publicado: (2021)

Do patients with ankylosing spondylitis adapt to their disease? Evidence from a ‘then-test’ in patients treated with TNF inhibitors
por: Essers, Ivette, et al.
Publicado: (2015)

Persistence, Discontinuation, and Switching Patterns of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients in the United States
por: Hunter, Theresa, et al.
Publicado: (2019)

Association of anti-TNF-α treatment with gut microbiota of patients with ankylosing spondylitis
por: Dai, Qinghong, et al.
Publicado: (2022)

Exploring the Extracellular Vesicle MicroRNA Expression Repertoire in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with TNF Inhibitors
por: Wielińska, Joanna, et al.
Publicado: (2021)

Safe Re-administration of Tumor Necrosis Factor-alpha (TNFα) Inhibitors in Patients with Rheumatoid Arthritis or Ankylosing Spondylitis Who Developed Active Tuberculosis on Previous Anti-TNFα Therapy
por: Suh, Young Sun, et al.
Publicado: (2014)

Ankylosing spondylitis patients at risk of poor radiographic outcome show diminishing spinal radiographic progression during long-term treatment with TNF-α inhibitors
por: Maas, Fiona, et al.
Publicado: (2017)

TNF-α inhibitor therapy can improve the immune imbalance of CD4+ T cells and negative regulatory cells but not CD8+ T cells in ankylosing spondylitis
por: Yang, Mingcan, et al.
Publicado: (2020)

RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?
por: Strand, Vibeke
Publicado: (2021)

Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study
por: Rotar, Ziga, et al.
Publicado: (2020)

Effect of Tumor Necrosis Factor Inhibitor Therapy on Osteoclasts Precursors in Ankylosing Spondylitis
por: Perpétuo, Inês P., et al.
Publicado: (2015)

The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis
por: Lee, Suhwan, et al.
Publicado: (2019)

Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: A meta-analysis
por: Ma, Zeren, et al.
Publicado: (2017)

Influence of IL10 (rs1800896) Polymorphism and TNF-α, IL-10, IL-17A, and IL-17F Serum Levels in Ankylosing Spondylitis
por: Braga, Matheus, et al.
Publicado: (2021)

TNF-alpha antagonists for treatment of juvenile ankylosing spondylitis
por: Orbán, I, et al.
Publicado: (2011)

IL-17A induces osteoblast differentiation by activating JAK2/STAT3 in ankylosing spondylitis
por: Jo, Sungsin, et al.
Publicado: (2018)

Imbalance between HAT and HDAC Activities in the PBMCs of Patients with Ankylosing Spondylitis or Rheumatoid Arthritis and Influence of HDAC Inhibitors on TNF Alpha Production
por: Toussirot, Eric, et al.
Publicado: (2013)

Improvement of conjunctival cytological grade and tear production in Ankylosing Spondylitis patients under TNF inhibitors: a long-term follow-up
por: Usuba, Fany Solange, et al.
Publicado: (2020)

The Association Between TNF Inhibitor Therapy Availability and Hospital Admission Rates for Patients with Ankylosing Spondylitis. A Longitudinal Population-Based Study
por: Nossent, Johannes, et al.
Publicado: (2021)

TNF-α inhibitors: are they carcinogenic?
por: Raval, Girindra, et al.
Publicado: (2010)

TNF-α Inhibitors Decrease Classical CD14(hi)CD16− Monocyte Subsets in Highly Active, Conventional Treatment Refractory Rheumatoid Arthritis and Ankylosing Spondylitis
por: Batko, Bogdan, et al.
Publicado: (2019)

IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients
por: Milanez, Fernanda Manente, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_dpjqodgopgi10u84octk8c94ue